



Addiction Medications Table

Week 6

CH

THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 6 MEDICATION TABLE DROPBOX BY SUNDAY

Drug Name	Indication Neurotransmitter(s) Affected Target Symptoms	Half-life (T1/2), Metabolism (CYP 450 enzyme)	Notable Side Effects (link to NT or affected brain circuit)	Initial Dosing C Specific lifespan pregnancy, bre
Buprenorphine (Subutex)	Indication Maintenance treatment of opioid dependence. Maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to moderate doses of a transmucosal buprenorphine- containing product. Neurotransmitter(s) Affected Mu opioid receptor partial agonist Kappa opioid receptor antagonist Target Symptoms Opioid dependence	Half-life Elimination half- life of sublingual is 22-42 hours. CYP450 Metabolized by CYP3A4	Notable Side Effects Headache constipation, nausea. Oral hypoesthesia, glossodynia Orthostatic hypotension. Respiratory depression. (link to NT or affected brain circuit) Side effects are linked to the binding of medication at the mu opioid receptors	Initial dosing Sublingual: Day Day 2: 12-16 m Increase in inc 4 mg, maximum Age considera Safety/effectiv established for product. Use with cauti Use with cauti with cardiac im Monitor patien depression Pregnancy Use only if ben neonatal opioi occur. Breast feeding passes into mil sedation/poor

Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.



Addiction Medications Table

Week 6

CH

--	--	--	--	--